Abstract:Inflammation is an integral component of cardiovascular disease and is thought to contribute to cardiac dysfunction and heart failure. While ischemia-induced inflammation has been extensively studied in the heart, relatively less is known regarding cardiac inflammation during non-ischemic stress. Recent work has implicated a role for Yes-associated protein (YAP) in modulating inflammation in response to ischemic injury; however, whether YAP influences inflammation in the heart during non-ischemic stress is not described. We hypothesized that YAP mediates a pro-inflammatory response during pressure overload (PO)-induced non-ischemic injury, and that targeted YAP inhibition in the myeloid compartment is cardioprotective. In mice, PO elicited myeloid YAP activation, and myeloid-specific YAP knockout mice (YAP F/F ;LysM Cre ) subjected to PO stress had preserved systolic function, and attenuated pathological remodeling compared to control mice. Inflammatory indicators were also significantly attenuated, while pro-resolving genes including Vegfa were enhanced, in the myocardium of myeloid YAP KO mice after PO. Experiments using bone marrow-derived macrophages (BMDMs) from YAP KO and control mice demonstrated that YAP suppression shifted polarization toward a resolving phenotype. We also observed attenuated NLRP3 inflammasome priming and function in YAP deficient BMDMs, as well as in myeloid YAP KO hearts following PO, indicating disruption of inflammasome induction. Studies in RAW264.7 cells demonstrated the effectiveness of pharmacological YAP inhibition using verteporfin to attenuate pro-inflammatory gene expression, and augment VEGFA levels. Finally, we leveraged nanoparticle-mediated delivery of verteporfin and observed attenuated PO-induced pathological remodeling and inflammation compared to DMSO nanoparticle control treatment. These data implicate myeloid YAP as an important molecular nodal point that facilitates cardiac inflammation and fibrosis during PO stress and suggest that selective inhibition of YAP may prove a novel therapeutic target in non-ischemic heart disease.

Yes-Associated Protein in Atherosclerosis and Related Complications: A Potential Therapeutic Target That Requires Further Exploration

The regulation of yes-associated protein/transcriptional coactivator with PDZ-binding motif and their roles in vascular endothelium

Yes-associated Protein and Transcriptional Coactivator with PDZ-binding Motif As New Targets in Cardiovascular Diseases

A review on decoding the roles of YAP/TAZ signaling pathway in cardiovascular diseases: Bridging molecular mechanisms to therapeutic insights

YAP/TAZ: Molecular pathway and disease therapy

Activation of Yes-Associated Protein/PDZ-Binding Motif Pathway Contributes to Endothelial Dysfunction and Vascular Inflammation in AngiotensinII Hypertension

The Multifaceted Roles of Hippo-YAP in Cardiovascular Diseases

The induction of yes-associated protein expression after arterial injury is crucial for smooth muscle phenotypic modulation and neointima formation.

YAP at the Progression of Inflammation

Macrophage K63-Linked Ubiquitination of YAP Promotes Its Nuclear Localization and Exacerbates Atherosclerosis

An updated review of YAP: A promising therapeutic target against cardiac aging?

The Hippo-YAP Pathway in Various Cardiovascular Diseases: Focusing on the Inflammatory Response

The role of Hippo/yes‐associated protein signalling in vascular remodelling associated with cardiovascular disease

YAP/TAZ as mechanobiological signaling pathway in cardiovascular physiological regulation and pathogenesis

The Role of Hippo/YAP Signaling in Vascular Remodeling and Related Diseases.

Recent advances in the role of Yes-associated protein in dermatosis

C-Abl Regulates YAPY357 Phosphorylation to Activate Endothelial Atherogenic Responses to Disturbed Flow.

Abstract P3091: Suppression Of Myeloid Yap Antagonizes Adverse Cardiac Remodeling During Pressure Overload Stress

P4HA2-induced prolyl hydroxylation of YAP1 restricts vascular smooth muscle cell proliferation and neointima formation

Atheroprotective laminar flow inhibits Hippo pathway effector YAP in endothelial cells

Yes-Associated Protein Targets the Transforming Growth Factor Β Pathway to Mediate High-Fat/High-Sucrose Diet-induced Arterial Stiffness.